Cyclacel Pharmaceuticals, Inc. (CYCC)

Cyclacel Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	0.01	0.04	0.42	-	-	-
Revenue Growth (YoY)	-87.50%	-89.76%	-	-	-	-
Gross Profit	0.01	0.04	0.42	-	-	-
Selling, General & Admin	7.63	5.39	6.72	7.38	7.46	5.88
Research & Development	2.74	6.66	19.16	20.27	14.93	4.76
Operating Expenses	10.37	12.05	25.87	27.66	22.39	10.64
Operating Income	-10.36	-12	-25.45	-27.66	-22.39	-10.64
Interest & Investment Income	0.05	0.01	0.27	0.21	0.02	0.04
Currency Exchange Gain (Loss)	-0.07	-0.05	-0.41	0.23	0.04	0.02
Other Non Operating Income (Expenses)	0.01	0.05	0.05	1.3	0.14	0.89
EBT Excluding Unusual Items	-10.37	-11.99	-25.55	-25.92	-22.19	-9.68
Pretax Income	-5.42	-11.99	-25.55	-25.92	-22.19	-9.68
Income Tax Expense	0.99	-0.78	-3	-4.72	-3.73	-1.24
Earnings From Continuing Operations	-6.41	-11.21	-22.56	-21.2	-18.46	-8.45
Net Income	-6.41	-11.21	-22.56	-21.2	-18.46	-8.45
Preferred Dividends & Other Adjustments	-	-	0.2	0.2	0.2	3.98
Net Income to Common	-6.41	-11.21	-22.76	-21.4	-18.66	-12.42
Shares Outstanding (Basic)	1	0	-	-	-	-
Shares Outstanding (Diluted)	1	0	-	-	-	-
EPS (Basic)	-4.76	-502.46	-	-	-	-
EPS (Diluted)	-4.76	-502.46	-	-	-	-
Free Cash Flow	-	-7.99	-16.12	-20.83	-18.57	-8.03
Free Cash Flow Per Share	-	-358.07	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	-	-	-
Operating Margin	-103580.00%	-27916.28%	-6060.24%	-	-	-
Profit Margin	-64080.00%	-26074.42%	-5418.10%	-	-	-
Free Cash Flow Margin	-	-18581.40%	-3837.62%	-	-	-
EBITDA	-10.35	-12	-25.42	-27.62	-22.35	-10.62
D&A For EBITDA	0.01	0.01	0.03	0.03	0.04	0.02
EBIT	-10.36	-12	-25.45	-27.66	-22.39	-10.64
Revenue as Reported	0.04	0.04	0.42	-	-	-

Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q